After successful inspection, the US Food and Drug Administration has issued zero 483 observations for Spain facility.
The JV allows Strides to get access to Vivimed’s US FDA compliant formulation plant in Alathur, Tamil Nadu in addition to a portfolio of approved abbreviated new drug applications (ANDAs) and under development product pipeline for US market.
CNBC-TV18 learns from sources that Vivimed Labs is exploring various options to grow its US generics market and selling stake in the Chennai formulation plant.
The company plans to invest a total of around USD 84 million for expansion. Of this, USD 68.5 million will be raised by debt, which includes a loan from World Bank arm International Finance Corporation.
In an interview to CNBC-TV18, Deven Choksey, MD of KRChoksey Investment Managers shared his readings and outlook on specific stocks that came out with good quarterly numbers.
Tata Motors | Sun Pharma | DLF | Cadila Health | Jindal Steel | SpiceJet | Adani Enterprises | MOIL | Cox & Kings | HDIL | Liberty Shoes | Voltas | National Fertilisers | Ashiana Housing | Power Mech | Intellect Design Arena are stocks, which are in the news today.
TCS | Maruti Suzuki | ONGC | Bharti Airtel | NTPC | SpiceJet | Mahindra & Mahindra | Hathway Cable | Vivimed Labs | Idea Cellular | Bharat Financial Inclusion | KCP Sugar | Mahindra Lifespaces and Electrosteel Castings are stocks, which are in the news today.
Nylim Jacob Ballas India Fund III LLC sold 984,000 shares of Vivimed Labs at Rs 94.47 per share on the NSE.
Kotak Mahindra (International) Limited sold 12,19,300 shares of Vivimed Labs at Rs 89.47.
Idea Cellular | Lupin | Tata Power | Bharat Forge | Oil India | National Fertilizers | Wanbury | Vivimed Labs | Ramco Cements | Sarda Energy | HCC | Indian Hotels | Eros International and SAIL are stocks, which are in the news today.
The company's 'Finished Dosage Form' manufacturing facility has had a favourable outcome post its US Food and Drug Administration (USFDA) inspection, Vivimed Labs said in a filing to BSE.
SP Tulsian of sptulsian.com tells CNBC-TV18 why he would not give a buy call on MRF stock which touched Rs 50,000-mark in trade Wednesday. He also shares his take on other tyre stocks.
CNBC-TV18's Ekta Batra lists out stocks that you should focus on.
Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have Aurobindo Pharma, Tata Global, Vivimed, Manpasand Beverages, and Bharti Airtel.
Watch accompanying video of CNBC-TV18's Mangalam Maloo, in which he tells more about Ashish Kacholia, his portfolio & his investment mantras.
In an interview to CNBC-TV18's Latha Venkatesh and Anuj Singhal, SP Tulsian of sptulsian.com shared his readings and outlook on specific stocks and sectors.
On September 27, 2016 Nylim Jacob Ballas India Fund III LLC sold 11,25,000 shares of Vivimed Labs at Rs 96.80 and sold 37,50,000 shares at Rs 90.64.
Here are a few stocks picked up by CNBC-TV18's analysts to focus today - stocks expected to gain are IGL, Vivimed Labs, Balaji Telefilms, ARSS infra, Motherson Sumi, Aurobindo Pharma, MPhasis and Tata Global Beverages while stocks expected to be under pressure are REC, Manpasand Beverages, Ahluwalia Contracts and Bajaj Finserv.
M&M | Lupin | Torrent Pharma | Cadila | Ahluwalia Contracts | RBL Bank | Jindal Stainless | Dalmia Bharat | Cenlub Industries | ARSS Infra | Maithan Alloys | Balaji Telefilms and Manpasand Beverages are stocks, which are in the news today.
Vivimed Labs shares touched record high of Rs 98.10, up 14.7 percent intraday after a large block deal on the exchange.
Anand Rathi is bullish on Vivimed Labs has recommended buy rating on the stock with a target price of Rs 133 in its research report dated August 17, 2016.
Axis Bank | Cairn India | Vedanta | Canara Bank | Hinduja Ventures | IL&FS Engineering | IOC | ONGC | BPCL | Chennai Petroleum | Godawari Power | Cyient | Vivimed Labs | ITI | Gujarat Fluorochemicals | Religare Enterprises and Ponni Sugar are stocks, which are in the news today.
The company had posted a net profit of Rs 17.94 crore in the January-March period of 2014-15 fiscal, Vivimed Labs said in a BSE filing.
Ajay Srivastava, CEO, Dimensions Consulting, cautions against going short on other sectors though fourth quarter numbers in most cases are expected to worse than the third quarter numbers. That is because there is too much liquidity in the system right now forcing share prices higher in the short term irrespective of fundamentals
Vivimed Labs has reported a consolidated total income from operations of Rs 331.88 crore and a net profit of Rs 23.02 crore for the quarter ended Dec '15